Myriad Genetics announces inclusion of breast density to MyRisk test

Myriad Genetics announced its MyRisk Hereditary Cancer Test with RiskScore now incorporates breast density using Tyrer-Cuzick version 8 to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer. Breast density plays a critical role in breast cancer screening and diagnosis. The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024. The incorporation of this critical piece of information into MyRisk with RiskScore, and Myriad’s recently launched cancer risk assessment program, is expected to help providers and their imaging networks offer more personalized patient care and detect breast cancer in its early stages, when there is the greater chance of a cure.